Article info

other Versions

PDF

Original Article
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Authors

  1. Correspondence to Dr Derralynn A Hughes, Department of Hematology, Royal Free London NHS Foundation Trust and University College London, London NW3 2PF, UK; rmgvdah{at}ucl.ac.uk
View Full Text

Citation

Hughes DA, Nicholls K, Shankar SP, et al
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Publication history

  • Received July 19, 2016
  • Revised October 7, 2016
  • Accepted October 12, 2016
  • First published November 10, 2016.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.